161 related articles for article (PubMed ID: 21700627)
1. The urgent need for new antibacterial agents.
Wise R;
J Antimicrob Chemother; 2011 Sep; 66(9):1939-40. PubMed ID: 21700627
[No Abstract] [Full Text] [Related]
2. The antibacterial drugs market.
Kresse H; Belsey MJ; Rovini H
Nat Rev Drug Discov; 2007 Jan; 6(1):19-20. PubMed ID: 17269159
[No Abstract] [Full Text] [Related]
3. The antibiotic pipeline--challenges, costs, and values.
Wenzel RP
N Engl J Med; 2004 Aug; 351(6):523-6. PubMed ID: 15295041
[No Abstract] [Full Text] [Related]
4. Update on the antibacterial resistance crisis.
Croft AC; D'Antoni AV; Terzulli SL
Med Sci Monit; 2007 Jun; 13(6):RA103-18. PubMed ID: 17534243
[TBL] [Abstract][Full Text] [Related]
5. Antibiotics at the crossroads.
Nathan C
Nature; 2004 Oct; 431(7011):899-902. PubMed ID: 15496893
[No Abstract] [Full Text] [Related]
6. Antibacterial drug discovery: is it all downhill from here?
Projan SJ; Shlaes DM
Clin Microbiol Infect; 2004 Nov; 10 Suppl 4():18-22. PubMed ID: 15522036
[TBL] [Abstract][Full Text] [Related]
7. Antibacterial research and development in the 21(st) Century--an industry perspective of the challenges.
Thomson CJ; Power E; Ruebsamen-Waigmann H; Labischinski H
Curr Opin Microbiol; 2004 Oct; 7(5):445-50. PubMed ID: 15451498
[TBL] [Abstract][Full Text] [Related]
8. Antibiotics: a shot in the arm.
Leeb M
Nature; 2004 Oct; 431(7011):892-3. PubMed ID: 15496888
[No Abstract] [Full Text] [Related]
9. Effective antibacterials: at what cost? The economics of antibacterial resistance and its control.
White AR;
J Antimicrob Chemother; 2011 Sep; 66(9):1948-53. PubMed ID: 21700625
[TBL] [Abstract][Full Text] [Related]
10. The role of the pharmaceutical industry in meeting the public health threat of antibacterial resistance.
Bergström R
Drug Resist Updat; 2011 Apr; 14(2):77-8. PubMed ID: 21493123
[TBL] [Abstract][Full Text] [Related]
11. Drug companies snub antibiotics as pipeline threatens to run dry.
Clarke T
Nature; 2003 Sep; 425(6955):225. PubMed ID: 13679874
[No Abstract] [Full Text] [Related]
12. The 10 x '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020.
Infectious Diseases Society of America
Clin Infect Dis; 2010 Apr; 50(8):1081-3. PubMed ID: 20214473
[TBL] [Abstract][Full Text] [Related]
13. A call to arms.
Nat Rev Drug Discov; 2007 Jan; 6(1):8-12. PubMed ID: 17269158
[No Abstract] [Full Text] [Related]
14. The drug-resistant bacteria that pose the greatest health threats.
Willyard C
Nature; 2017 Feb; 543(7643):15. PubMed ID: 28252092
[No Abstract] [Full Text] [Related]
15. Drug development: Time for teamwork.
May M
Nature; 2014 May; 509(7498):S4-5. PubMed ID: 24784427
[No Abstract] [Full Text] [Related]
16. Biologics target bad bugs.
Extance A
Nat Rev Drug Discov; 2010 Mar; 9(3):177-8. PubMed ID: 20190776
[No Abstract] [Full Text] [Related]
17. A guiding hand for antibiotics.
Jones D
Nat Rev Drug Discov; 2011 Mar; 10(3):161-2. PubMed ID: 21358722
[No Abstract] [Full Text] [Related]
18. Antibiotic utilisation surveillance from pharmacoeconomic/pharmacotherapeutic standpoint with control of bacterial resistance.
Stefan-Mikić S
Med Pregl; 2008; 61 Suppl 1():7-8. PubMed ID: 19256063
[No Abstract] [Full Text] [Related]
19. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE.
Rice LB
J Infect Dis; 2008 Apr; 197(8):1079-81. PubMed ID: 18419525
[No Abstract] [Full Text] [Related]
20. Regulatory opportunities to encourage technology solutions to antibacterial drug resistance.
Finch R;
J Antimicrob Chemother; 2011 Sep; 66(9):1945-7. PubMed ID: 21700629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]